Manual for the Completion of CDISC Aligned NCI Standard Case Report Form (CRF) Modules

Introduction

In 2006, members of the National Cancer Institute's Center for Biomedical Informatics and Information Technology (NCI CBIIT) in conjunction with the cancer Data Standards Registry and Repository (caDSR) user community initiated a Case Report Form (CRF) harmonization activity. CRFs submitted from the community were reviewed and inventoried. The Harmonization group then reviewed all questions on the CRF and partitioned them into four categories:

- Mandatory A data collection variable that must be on the CRF (e.g., a regulatory requirement (if applicable)).
- Conditional A data collection variable that must be collected on the CRF for specific cases that may be dictated by local or sponsor defined business rules.
- Optional A data collection variable that is available for use if needed. There is no regulatory or business requirement for inclusion of this element on the CRF; if the design and scientific questions posed in the study dictate the need to collect this type of data; this is the element to include on the CRF.
- Non-harmonized A data collection variable that is, by consensus, to primarily belong to a different CRF module or is not belonging to any defined module.

A template form with modules that contain questions or variables representing data to be collected and a companion electronic CRF instruction manual was developed. These CRF modules were vetted and adopted by the caDSR stakeholder community as metadata standards.

Since the original CRFs and manuals were adopted, the Food & Drug Administration (FDA) published guidelines for submission of clinical trial study data using the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) for Investigational New Drug (IND) trials starting after December 2017. In response, NCI CBIIT has aligned the NCI Standard CRF modules with the CDISC data collection standard, Clinical Data Acquisition Standards Harmonization (CDASH) where data is expected to be submitted to FDA in SDTM format.

The instruction manual is a set of directions to guide data collection in each module template. Specific implementation instructions are not present; various groups may wish to implement the contents of a module in a variety of software applications.

The instructions include the field name, description or definition of each field, and any special formatting notes that apply to entries – such as the inclusion of full dates, use of values from a choice list only, etc. Finally, each question (or data item) is noted as Mandatory (m), Conditional (c), or Optional (o).

Progression CDISC Aligned NCI Standard Template Module Definitions

Mapping to the CDASH:

N/A

Mapping to the SDTM:

This NCI Standard Template Form maps to the following domains in the SDTMIG v3.3 metadata table:

- RS Disease Response and Clin Classification (v3.3)
- TU Tumor/Lesion Identification (v3.3)

Progression CDISC Aligned NCI Standard Template Module Template Instructions

Field Descriptions and Instructions

Field Name (Partition Status) CDE ID # Short Name	Definition CDISC Mapping and Instruction	Format
Disease Response Most Recent Evaluation Date (o) 7038803 RSMTRDT	The date disease response was evaluated, represented in an unambiguous date format (e.g., DD-MON-YYYY). CDASH: No Match; SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "RTNPRGEV" RSTEST (6620604) = "Most Recent Disease Status Evaluation"	DATE
Progressive Disease Or Recurrent Disease Present Indicator (o) 7038804 RLPGIND	The indication of whether or not progressive disease or recurrent disease was present. CDASH: No Match; SDTM: RSORRES (6642369) where RSTESTCD (6620609) = "RLPGIND" and RSTEST (6620604)= "Disease progress or relapse indicator"	CHARACTER. Use choice list.

Field Name (Partition Status) CDE ID # Short Name	Definition CDISC Mapping and Instruction	Format
Disease Response Most Recent Negation Evaluation Text (o)	The description of the reason disease status was not evaluated.	CHARACTER
7038805 RSDZRPTX	CDASH: No Match; SDTM: RSREASND (6642040)	
Progressive Disease Or Recurrent Disease Post Last Personal Contact Present Type (o)	The indication of the type of progressive disease or recurrent disease.	CHARACTER. Use choice list.
7038806 PRGRCNT	CDASH: No Match; SDTM: RSORRES (6642369) where RSTESTCD (6620609) = "PRGRCNT" and RSTEST (6620604) = "Progressive/recurrent disease"	
Progressive Disease or Recurrent Disease Evaluation Date (o) 7038807	The date progressive disease or recurrent disease was identified, represented in an unambiguous date format (e.g., DD-MON-YYYY).	DATE
RSPRGDT	CDASH: No Match; SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation"	
Progressive Disease Anatomic Site (o)	The anatomic site where progressive disease occurred.	CHARACTER. Use choice list.
7038808 TUPGDZST	CDASH: No Match; SDTM: TULOC (6621372)	
Progressive Disease Anatomic Site Text (o) 7038809	ext progressive disease occurred not previously listed.	
TULOCX	CDASH: No Match; SDTM: TULOC (6621372)	
Disease Response Evaluation Method Type disease response. (o)		CHARACTER. Use choice list.
7038810 TUEVALTP	CDASH: No Match; SDTM: TUMETHOD (No CDE)	

Annotated CRF: Progression CDISC Aligned NCI Standard Template

This annotated CRF is ONLY used to show CDISC mapping without consideration of the CRF layout. CDASH mapping is in **Blue**, and SDTM mapping is in **Red**.

Form Name: Progression CDISC Aligned NCI Standard Template Optional Questions

CRF	Question		Value Domain
eval	e of most recent disease status luation (7038803) E Short Name: RSMTRDT		DATE – Maximum Length = 11
[CDASH: No Match		
	SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "RTNPRGEV" RSTEST (6620604) = "Most Recent Disease Status Evaluation"		
duri	the patient's disease progress or relaping the indicated period? (7038804) Short Name: RLPGIND	se	CHARACTER – Maximum Length = 2
CDE	Short Name: REFGIND		□ N – No
	CDASH: No Match		□ NA – Not Applicable□ U – Unknown
	SDTM: RSORRES (6642369) where RSTESTCD (6620609) = "RLPGIND" and RSTEST (6620604)= "Disease progress or relapse indicator"		□ Y – Yes
(703	valuation was not done specify reason 88805) E Short Name: RSDZRPTX		CHARACTER – Maximum Length = 200
[CDASH: No Match		
[SDTM: RSREASND (6642040)		

Disease Progression First regional recurrence – First Regional Recurrent Malignant Neoplasm Progression – Disease Progression Progression/Recurrence (NOS) – Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40	CRF Question	Value Domain
Recurrent Malignant Neoplasm Distant progression – Distant Disease Progression Distant progression – First Distant Disease Progression Progression Progression Prist distant progression Prist Distant Disease Progression Prist Distant Progression Prist Distant Disease Progression Prist Distant Disease Progression Prist Distant Progression Prist Distant Disease Progression Prist Distant Progr	, ,	CHARACTER – Maximum Length = 30
Distant progression - Distant Disease Progression First distant progression - First Distant Disease Progression First distant progression - First Distant Disease Progression First distant progression - First Distant Disease Progression First distant recurrence - First Local Recurrent Malignant Neoplasm First local progression - First Local Disease Progression First local progression - First Local Disease Progression First local progression - First Regional Disease Progression First regional progression - First Regional Recurrent Malignant Neoplasm Progression - Disease Progression Progression - Disease Progression Progression Progression - First Regional Recurrent Malignant Neoplasm Progression Recurrence (NOS) - Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence - Recurrent Malignant Neoplasm Symptomatic deterioration - Symptomatic Deterioration Date of progression (or relapse) (7038807) DATE - Maximum Length = 11 DATE - Maximum Length = 11 DATE - Maximum Length = 12 DATE - Maximum Length = 13 DATE - Maximum Length = 40 DATE	CDASU, No Motob	
SDTM: RSORRES (6642369) where RSTESTCD (6620604) = "Progressive/recurrent disease" First distant progression - First Distant Disease Progression First Local Recurrent Malignant Neoplasm First local recurrence - First Local Disease Progression First local recurrent Malignant Neoplasm First local recurrent Malignant Neoplasm First regional progression - First Regional Disease Progression First regional progression - First Regional Recurrent Malignant Neoplasm First regional recurrence - First Regional Recurrent Malignant Neoplasm Progression Recurrent Malignant Neoplasm Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence - Recurrent Malignant Neoplasm Symptomatic deterioration - Symptomatic Deterioration Date of progression (or relapse) (7038807) DATE - Maximum Length = 11 Date of progression (6651952) where RSTESTCD (6651952) where RSTESTCD (6620604) = "Progressive/recurrent disease evaluation" CHARACTER - Maximum Length = 40	CDASH: No Match	☐ Distant progression – Distant Disease
First distant recurrence – First Local Recurrent Malignant Neoplasm First local progression – First Local Disease Progression First local recurrence – First Local Disease Progression First local recurrence – First Local Recurrent Malignant Neoplasm First regional progression – First Regional Recurrent Malignant Neoplasm First regional recurrence – First Regional Recurrent Malignant Neoplasm Progression – Disease Progression Progression Recurrence (NOS) – Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) DATE – Maximum Length = 11 DATE – Maximum Length = 11 DATE – Maximum Length = 11 SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" CHARACTER – Maximum Length = 40 CHARACTER – Maximu	RSTESTCD (6620609) = "PRGRCNT"	☐ First distant progression – First Distant
Disease Progression First local recurrence – First Local Recurrent Malignant Neoplasm First regional progression – First Regional Disease Progression First regional progression – First Regional Disease Progression Progression – Disease Progression Progression – Disease Progression Progression Recurrence (NOS) – Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT DATE – Maximum Length = 11 CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620604) = "Progressive/recurrent disease evaluation" CHARACTER – Maximum Length = 40		
Recurrent Malignant Neoplasm First regional progression – First Regional Disease Progression First regional recurrence – First Regional Recurrent Malignant Neoplasm Progression – Disease Progression Progression Recurrence (NOS) – Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		
Disease Progression First regional recurrence – First Regional Recurrent Malignant Neoplasm Progression – Disease Progression Progression/Recurrence (NOS) – Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		
Recurrent Malignant Neoplasm Progression – Disease Progression Progression/Recurrence (NOS) – Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" CHARACTER – Maximum Length = 40		= 1 ot 1 og 1
Progression/Recurrence (NOS) – Disease Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		
Progression Recurrent Malignant Neoplasm Not Otherwise Specified Recurrence – Recurrent Malignant Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		☐ Progression – Disease Progression
Neoplasm Symptomatic deterioration – Symptomatic Deterioration Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		Progression Recurrent Malignant
Date of progression (or relapse) (7038807) CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		
CDE Short Name: RSPRGDT CDASH: No Match SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		☐ Symptomatic deterioration – Symptomatic Deterioration
SDTM: RSDTC (6651952) where RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40		DATE – Maximum Length = 11
RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease evaluation" Sites of progression (7038808) CHARACTER – Maximum Length = 40	CDASH: No Match	
	RSTESTCD (6620609) = "PRGREEV", RSTEST (6620604) = "Progressive/recurrent disease	
CDF Short Name: TUPGDZST	Sites of progression (7038808) CDE Short Name: TUPGDZST	CHARACTER – Maximum Length = 40
List of 91 PVs		List of 91 PVs
CDASH: No Match	CDASH: No Match	
SDTM: TULOC (6621372)	SDTM: TULOC (6621372)	

CRF Question	Value Domain
Other specify (7038809) CDE Short Name: TULOCX	CHARACTER – Maximum Length = 200
CDASH: No Match	
SDTM: TULOC (6621372)	
What was the method used to determine progression or recurrence? (7038810) CDE Short Name: TUEVALTP CDASH: No Match SDTM: TUMETHOD (No CDE)	CHARACTER – Maximum Length = 25 ☐ Biomarkers – Biomarker ☐ Clinical Assessment – Clinical Assessment Tool ☐ Cytogenetics – Cytogenetic Analysis ☐ Imaging – Imaging Technique ☐ Immunological – Immunologic Technique
	 □ Laboratory Test(s) – Laboratory Procedure □ Molecular – Molecular Analysis □ Morphologic – Morphologic Finding □ Pathologic – Pathologic Finding